Connect your AI

Nuvation Bio NUVB Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers SquibbBMY

$1.1B-43.5%

PfizerPFE

$2.62B+12.0%

Nuvalent, Inc.NUVL

-$92.4M-68.5%

ImmunomeIMNM

-$58.64M-10.5%

ArriVent BioPharma, Inc.AVBP

-$41.89M+38.4%

Arcus BiosciencesRCUS

-$138M-4.5%

Other financials

Income statement

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

Market cap$2.1B+150%

Enterprise value$2.03B+154%

P/S14.7×-62.0×

Profitability

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nuvation Bio's operating cash flow?: Nuvation Bio (NUVB) reported operating cash flow of $5.07M in Q1 2026.
How has Nuvation Bio's operating cash flow changed year-over-year?: Nuvation Bio's operating cash flow increased by 111.9% year-over-year, from -$42.63M to $5.07M.
What is the long-term trend for Nuvation Bio's operating cash flow?: Over 4 years (2021 to 2025), Nuvation Bio's operating cash flow has grown at a 26.3% compound annual growth rate (CAGR), from -$68.19M to -$173.43M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.